New combo aims to treat brain metastases while protecting memory
NCT ID NCT07505173
First seen Apr 08, 2026 · Last updated Jun 20, 2026 · Updated 12 times
Summary
This phase II trial is testing a new way to treat lung cancer that has spread to the brain. It combines a targeted cancer pill (osimertinib) with a special type of whole-brain radiation that tries to protect the memory center (hippocampus). The study will enroll 74 people with a specific EGFR gene mutation. The goal is to see if this approach can keep brain tumors under control longer while causing fewer thinking and memory problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NAIVE ADVANCED NON-SMALL CELL LUNG CANCER WITH EGFR-SENSITIVE MUTATIONS (EGFR EXON 19 DELETION AND EXON 21 L858R MUTATION) AND SYMPTOMATIC BRAIN METASTASES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute and Hospital
RECRUITINGTianjin, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
osimertinib (a targeted cancer pill) and radiation therapy
What this could lead to
If successful, this combination could offer a safer, more effective way to control brain metastases while better preserving memory and thinking skills.
What could go wrong
This is a small, early-phase study (74 people) with no comparison group, so results may not be definitive. Radiation to the brain always carries risks like fatigue, hair loss, and potential cognitive side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.